Abstract
Background
Myocardial damage after myocardial infarction (MI) was deemed irreversible after late reperfusion. Administration of multipotent stem cell (MSC) into such infarct may regenerate the myocardium and capillary network.
Hypothesis
Transcoronary infusion of bone marrow derived multipotent stem cells into infarcted related artery after acute myocardial infarction is feasible, safe and improve left ventricular function.
Methods
We conducted a pilot study in patients who survived ST‐elevation MI with late reperfusion therapy and remained hemodynamically stable. Bone marrow derived MSC was infused into a patent infarct‐related coronary artery during brief low pressure (2 atm) balloon inflation. A 3‐T gadolinium‐based MRI was performed at baseline and 8 weeks later to evaluate infarct area and LV function.
Results
We enrolled 10 patients, age 63.8 ± 2.8 years 5.2 ± 4.12 × 106 MSC were infused via coronary artery 24.8 ± 16 days after infarction. The procedures were successful in all patients without any in‐hospital event. Infarct size by MRI decreased by 5.84% (P = .018) over 8 weeks. Mean baseline left ventricular ejection fraction (LVEF) was 44.1% ± 9% and was 46.3% ± 9% at 8 weeks (P = .34). A trend of smaller LV end‐systolic volume with 65.02 ± 18.2 ml vs 63.04 ± 21.89 ml (P = .09) with no change of LV end‐diastolic volume observed.
Conclusion
MSC infusion into coronary circulation was feasible and safe after myocardial infarction. Infarct size was reduced with preservation of LV geometry. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (297.9 KB).
References
- 1. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981–2988. [DOI] [PubMed] [Google Scholar]
- 2. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701–705. [DOI] [PubMed] [Google Scholar]
- 3. Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ Res 2005; 96: 151–163. [DOI] [PubMed] [Google Scholar]
- 4. Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005; 115: 326–338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913–1918. [DOI] [PubMed] [Google Scholar]
- 6. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE‐AMI). Circulation 2002; 106: 3009–3017. [DOI] [PubMed] [Google Scholar]
- 7. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. Lancet 2004; 364: 141–148. [DOI] [PubMed] [Google Scholar]
- 8. Van de Werf F, Arnold A. Intravenous tissue plasminogen activator and size of infarct, left ventricular function and survival in acute myocardial infarction. BMJ 1988; 297: 1374–1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ottervanger J, van 't Hof A, Reiffers S, et al. Long‐term recovery of left ventricular function after primary angioplasty for acute myocardial infarction. Eur Heart J 2001; 22: 785–790. [DOI] [PubMed] [Google Scholar]
- 10. Garcia‐Dorado D, Oliveras J, Gili J, et al. Analysis of myocardial edema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc Res 1993; 27: 1462–1469. [DOI] [PubMed] [Google Scholar]
- 11. Kim RJ, Wu E, Rafael A, et al. The use of contrast‐enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445–1453. [DOI] [PubMed] [Google Scholar]
- 12. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906. [DOI] [PubMed] [Google Scholar]
- 13. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198–2202. [DOI] [PubMed] [Google Scholar]
- 14. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133‐positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112(suppl 9): I178–I183. [DOI] [PubMed] [Google Scholar]
- 15. Van de Werf F, Janssens S, Dubois C, et al. Autologous bone marrow‐derived stem‐cell transfer in patients with ST‐segment elevation myocardial infarction: double‐blind, randomised controlled trial. Lancet 2006; 367: 113–121. [DOI] [PubMed] [Google Scholar]